Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/17504995/ below:

Gene expression signature predicts recurrence in lung adenocarcinoma

Affiliations

• ¹ Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia. Jill_E_Larsen@health.qld.gov.au

• PMID: 17504995
• DOI: 10.1158/1078-0432.CCR-06-2525

Item in Clipboard

Jill E Larsen et al. Clin Cancer Res. 2007.

• ¹ Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia. Jill_E_Larsen@health.qld.gov.au

• PMID: 17504995
• DOI: 10.1158/1078-0432.CCR-06-2525

Item in Clipboard

Purpose: Improving outcomes for early-stage lung cancer is a major research focus at present because a significant proportion of stage I patients develop recurrent disease within 5 years of curative-intent lung resection. Within tumor stage groups, conventional prognostic indicators currently fail to predict relapse accurately.

Experimental design: To identify a gene signature predictive of recurrence in primary lung adenocarcinoma, we analyzed gene expression profiles in a training set of 48 node-negative tumors (stage I-II), comparing tumors from cases who remained disease-free for a minimum of 36 months with those from cases whose disease recurred within 18 months of complete resection.

Results: Cox proportional hazards modeling with leave-one-out cross-validation identified a 54-gene signature capable of predicting risk of recurrence in two independent validation cohorts of 55 adenocarcinomas [log-rank P=0.039; hazard ratio (HR), 2.2; 95% confidence interval (95% CI), 1.1-4.7] and 40 adenocarcinomas (log-rank P=0.044; HR, 3.3; 95% CI, 1.4-7.9). Kaplan-Meier log-rank analysis found that predicted poor-outcome groups had significantly shorter survival, and furthermore, the signature predicted outcome independently of conventional indicators of tumor stage and node stage. In a subset of earliest stage adenocarcinomas, generally expected to have good outcome, the signature predicted samples with significantly poorer survival.

Conclusions: We describe a 54-gene signature that predicts the risk of recurrent disease independently of tumor stage and which therefore has potential to refine clinical prognosis for patients undergoing resection for primary adenocarcinoma of the lung.

PubMed Disclaimer

• Expression profiling defines a recurrence signature in lung squamous cell carcinoma.

  Larsen JE, Pavey SJ, Passmore LH, Bowman R, Clarke BE, Hayward NK, Fong KM. Larsen JE, et al. Carcinogenesis. 2007 Mar;28(3):760-6. doi: 10.1093/carcin/bgl207. Epub 2006 Nov 1. Carcinogenesis. 2007. PMID: 17082175

• Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.

  Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, Macdonald J, Thomas D, Moskaluk C, Wang Y, Beer DG. Raponi M, et al. Cancer Res. 2006 Aug 1;66(15):7466-72. doi: 10.1158/0008-5472.CAN-06-1191. Cancer Res. 2006. PMID: 16885343

• A prognostic test for adenocarcinoma of the lung from gene expression profiling data.

  Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. Gordon GJ, et al. Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):905-10. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14504202

• Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts.

  Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, Socinski MA, Perou C, Meyerson M. Hayes DN, et al. J Clin Oncol. 2006 Nov 1;24(31):5079-90. doi: 10.1200/JCO.2005.05.1748. J Clin Oncol. 2006. PMID: 17075127 Review.

• Genomic prognostic models in early-stage lung cancer.

  Kratz JR, Jablons DM. Kratz JR, et al. Clin Lung Cancer. 2009 May;10(3):151-7. doi: 10.3816/CLC.2009.n.021. Clin Lung Cancer. 2009. PMID: 19443334 Review.

• YB-1, the E2F pathway, and regulation of tumor cell growth.

  Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. Lasham A, et al. J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28. J Natl Cancer Inst. 2012. PMID: 22205655 Free PMC article.

• Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors.

  Peinado-Serrano J, Carnero A. Peinado-Serrano J, et al. Cancers (Basel). 2022 Apr 28;14(9):2202. doi: 10.3390/cancers14092202. Cancers (Basel). 2022. PMID: 35565331 Free PMC article. Review.

• Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I-III lung adenocarcinoma.

  Zhang Y, Yang Z, Tang Y, Guo C, Lin D, Cheng L, Hu X, Zhang K, Li G. Zhang Y, et al. Genes Dis. 2022 Aug 5;10(4):1657-1674. doi: 10.1016/j.gendis.2022.07.005. eCollection 2023 Jul. Genes Dis. 2022. PMID: 37397559 Free PMC article.

• Gene expression profiles of lung adenocarcinoma linked to histopathological grading and survival but not to EGF-R status: a microarray study.

  Neumann J, Feuerhake F, Kayser G, Wiech T, Aumann K, Passlick B, Fisch P, Werner M, Zur Hausen A. Neumann J, et al. BMC Cancer. 2010 Mar 2;10:77. doi: 10.1186/1471-2407-10-77. BMC Cancer. 2010. PMID: 20196851 Free PMC article.

• Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

  Subramanian J, Simon R. Subramanian J, et al. J Natl Cancer Inst. 2010 Apr 7;102(7):464-74. doi: 10.1093/jnci/djq025. Epub 2010 Mar 16. J Natl Cancer Inst. 2010. PMID: 20233996 Free PMC article. Review.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3